Nrx Pharmaceuticals, Inc. (NRXP)

Trade NRXP now with
6/10/2022 11:55:19 PM NRx Pharma Says FDA Denies Breakthrough Therapy Designation Request For ZYESAMI
6/7/2022 9:12:31 PM NRx Pharma Appoints Seth Van Voorhees As CFO And Treasurer Effective June 13
5/26/2022 12:07:45 AM NRx Pharmaceuticals Announces DSMB Update On NIH Study Of ZYESAMI In Critical COVID-19
5/16/2022 7:32:27 AM NRx Pharma Q1 Net Loss $13.4 Mln Or $0.21/shr Vs Loss Of $25.5 Mln, Or $0.71/shr Prior Year
5/12/2022 8:18:31 AM NRx Announces Enrollment Of First Patient In Phase II Study Of Bipolar Depression With Sub-Acute Suicidality
4/21/2022 8:50:02 AM NRx Files Breakthrough Therapy Designation Request For ZYESAMI In Subgroup Of Patients With Critical COVID-19
3/31/2022 8:25:47 AM NRx:I-SPY COVID Trial Shows No Benefit With Addition Of ZYESAMI When Given By Mouth Inhalation In Ill COVID-19 Patients
3/31/2022 8:21:49 AM NRx Pharma FY Net Loss $93.1 Mln Or $1.98/shr Vs. Loss Of $51.8 Mln Or $1.51/shr Prior Year
3/18/2022 5:52:22 AM NRx Names Ira Strassberg As CFO
3/18/2022 5:12:38 AM NRx Pharma Appoints Ira Strassberg As CFO And Treasurer
3/8/2022 10:32:59 PM NRx Pharma Names Robert Besthof Interim CEO
2/15/2022 8:36:11 AM NRx Pharma : US National Institutes Of Health Study Of ZYESAMI In Critical COVID-19 Cleared To Complete Full Enrollment
2/2/2022 8:00:22 PM NRx Pharmaceuticals Announces Closing Of $25 Mln Private Placement